It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The human SLC22A6/OAT1 plays an important role in the elimination of a broad range of endogenous substances and xenobiotics thus attracting attention from the pharmacological community. Furthermore, OAT1 is also involved in key physiological events such as the remote inter-organ communication. Despite its significance, the knowledge about hOAT1 structure and the transport mechanism at the atomic level remains fragmented owing to the lack of resolved structures. By means of protein-threading modeling refined by μs-scaled Molecular Dynamics simulations, the present study provides the first robust model of hOAT1 in outward-facing conformation. Taking advantage of the AlphaFold 2 predicted structure of hOAT1 in inward-facing conformation, we here provide the essential structural and functional features comparing both states. The intracellular motifs conserved among Major Facilitator Superfamily members create a so-called “charge-relay system” that works as molecular switches modulating the conformation. The principal element of the event points at interactions of charged residues that appear crucial for the transporter dynamics and function. Moreover, hOAT1 model was embedded in different lipid bilayer membranes highlighting the crucial structural dependence on lipid-protein interactions. MD simulations supported the pivotal role of phosphatidylethanolamine components to the protein conformation stability. The present model is made available to decipher the impact of any observed polymorphism and mutation on drug transport as well as to understand substrate binding modes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Univ. Limoges, INSERM U1248 Pharmacology & Transplantation, CBRS, Faculté de Médecine et Pharmacie, Limoges, France (GRID:grid.9966.0) (ISNI:0000 0001 2165 4861)
2 Univ. Limoges, INSERM U1248 Pharmacology & Transplantation, CBRS, Faculté de Médecine et Pharmacie, Limoges, France (GRID:grid.9966.0) (ISNI:0000 0001 2165 4861); InSiliBio, Ester Technopôle, Limoges, France (GRID:grid.9966.0)
3 InSiliBio, Ester Technopôle, Limoges, France (GRID:grid.9966.0)
4 Univ. Limoges, INSERM U1248 Pharmacology & Transplantation, CBRS, Faculté de Médecine et Pharmacie, Limoges, France (GRID:grid.9966.0) (ISNI:0000 0001 2165 4861); CHU de Tours, Tours, France (GRID:grid.411167.4) (ISNI:0000 0004 1765 1600)
5 Univ. Limoges, INSERM U1248 Pharmacology & Transplantation, CBRS, Faculté de Médecine et Pharmacie, Limoges, France (GRID:grid.9966.0) (ISNI:0000 0001 2165 4861); CHU Limoges, Department of Pharmacology and Toxicology, Limoges, France (GRID:grid.411178.a) (ISNI:0000 0001 1486 4131)